Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. The study ...

Get insights on Biogen’s Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.

AstraZeneca ($AZN) announced an update on their ongoing clinical study. In a recent clinical study update, AstraZeneca has completed a Phase 2a ...

Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

Saffron, the stigmas of Crocus sativus L., has been used extensively in traditional herbal medicine. Since several years, the research interest in this plant is intense. Thus numerous clinical trials ...

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...

The agency said that although the Akeega with prednisone improved outcomes in all patients with HRR mutations, the benefits were driven by those with BRCA2 mutations.

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...

The phase 3 MINT study evaluated inebilizumab, a CD-19 directed cytolytic antibody, in 238 patients with gMG, including those who were anti-AChR-Ab+ and anti-MuSK-Ab+.

Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. Inebilizumab gains ...